6533b85cfe1ef96bd12bcb97

RESEARCH PRODUCT

Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

Cosimo Damiano InchingoloWalter EliseiFabio AielloG. GiorgettiGiovanni BrandimarteAntonio Tursi

subject

Malediverticular diseaseSeverity of Illness IndexGastroenterologychemistry.chemical_compoundReference ValuesProspective StudiesIntestinal MucosaMesalamineProspective cohort studyCell proliferationtreatmentmedicine.diagnostic_testAnti-Inflammatory Agents Non-SteroidalBiopsy Needledigestive oral and skin physiologyGastroenterologyColonoscopyMiddle AgedImmunohistochemistryDiverticulosisDose–response relationshipTreatment OutcomemesalazineDiverticular diseaseFemalemedicine.medical_specialtyCryptRisk Assessmentdigestive systemDrug Administration ScheduleStatistics NonparametricMesalazineInternal medicineBiopsyDiverticulosis ColonicmedicineHumansAgedProbabilityDose-Response Relationship DrugHepatologybusiness.industryCase-control studyEpithelial Cellsmedicine.diseasedigestive system diseasescolonic mucosaKi-67 AntigenchemistryCase-Control StudiesbusinessFollow-Up Studies

description

Background and aims: increased epithelial cell proliferation may be detected in diverticular disease, but antibiotics have failed in reducing it. We assess therefore the effect of mesalazine on epithelial cell proliferation in diverticular disease. Methods: a prospective study was conducted on 20 consecutive patients with a new endoscopic diagnosis of symptomatic uncomplicated diverticular disease. The patients were treated with mesalazine 1.6 mg/day for 1 year. The Ki-67 antigen index of the whole crypt and in the upper third was separately evaluated before and after starting the treatment. Results: cell proliferation index was higher in diverticular disease patients than healthy controls both in the whole crypt (median 6.7%, range 2–9% vs. median 1.6%, range 1–3%, p = 0.001) and in the upper third of the crypt (median 6.8%, range 2–8% vs. median 1.8%, range 1–3%, p = 0.001). Cell proliferation decreased throughout the follow-up. In the whole crypt it was 6.7% at entry and 3.8% at the end of treatment (p < 0.005), whereas it was 6.8% at entry and 2.9% at the end of treatment in the upper third of the crypt (p < 0.005). Conclusions: we found mesalazine effective in reducing the colonic cell proliferation in long-term treatment for colonic diverticular disease.

https://doi.org/10.1016/j.dld.2008.02.022